



Co-morbidities, Co-medications and Cancer

Guest Editor:

Dr. Sandar Tin Tin

1. Section of Epidemiology and
Biostatistics, School of
Population Health, University of
Auckland, Auckland, New
Zealand;
2. Cancer Epidemiology Unit,
Nuffield Department of
Population Health, University of
Oxford, Oxford, UK

Deadline for manuscript
submissions:

closed (30 June 2021)

Message from the Guest Editor

Cancer is common and rising as the population ages. It is becoming a chronic disease as cancer survival rates are improving with advances in diagnosis and treatment options. As a result, cancer patients are increasingly burdened with comorbidities such as cardiovascular disease and diabetes, which may increase their risk of being exposed to polypharmacy, i.e., the simultaneous use of multiple drugs.

Comorbidities and associated medication use may have an impact on cancer treatments and outcomes. For example, patients with comorbidities may be less likely to receive definitive cancer treatment and experience poorer survival outcomes. Polypharmacy may increase the risk of drug–drug interactions which may result in increased drug-related toxicity or impaired treatment efficacy, thereby impacting survival outcomes. On the other hand, certain noncancer medications such as metformin appear to have a positive effect on cancer outcomes.

This Topical Collection is open to the subject area of comorbidities, co-medications, and cancer. The keywords listed below provide an outline of some of the possible areas of interest.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Paul B. Tchounwou

RCMI Center for Urban Health
Disparities Research and
Innovation, Richard Dixon
Research Center, Morgan State
University, 1700 E. Cold Spring
Lane, Baltimore, MD 21251, USA

Message from the Editor-in-Chief

Addressing the environmental and public health challenges requires engagement and collaboration among clinicians and public health researchers. Discovery and advances in this research field play a critical role in providing a scientific basis for decision-making toward control and prevention of human diseases, especially the illnesses that are induced from environmental exposure to health hazards. *IJERPH* provides a forum for discussion of discoveries and knowledge in these multidisciplinary fields. Please consider publishing your research in this high quality, peer-reviewed, open access journal.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, PubMed, MEDLINE, PMC, Embase, GEOBASE, CAPus / SciFinder, and other databases.

Journal Rank: CiteScore - Q1 (Public Health, Environmental and Occupational Health)

Contact Us

*International Journal of
Environmental Research and Public
Health* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijerph
ijerph@mdpi.com
X@IJERPH_MDPI